![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Corporate information
Registration country
Company type
Innate immune drug development companyFunding rounds
Series C EUR 33,000,000
( )
Participants: BB Biotech Ventures (co-led the round), existing investor Novartis Venture Fund (co-led the round), Sunstone Capital, Baxter Ventures, Amgen Ventures, EMBL Ventures, existing investors Fountain Healthcare Partners, Roche Venture Fund, Seroba
| Investor | Profile | Country | |
|---|---|---|---|
|
Amgen Ventures | ||
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Baxter Ventures | ||
|
|
BB Biotech Ventures | ||
|
|
EMBL Ventures GmbH (EMBL Venture Capital) | ||
|
|
Fountain Healthcare Partners | ||
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | |
|
Roche Venture Fund | The corporate venture fund of the healthcare company Roche | |
|
|
Seroba Kernel Life Sciences Ltd | ||
|
Sunstone Capital AS |
Investment activity status
Active investor